ZTS stock news · Zoetis Inc.
Get alerts for ZTS
Follow Zoetis Inc. (ZTS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ZTSZoetis got the green light from the FDA for Convenia RTU to treat skin infections in dogs.
Good for ZTSZoetis received FDA approval for a dog skin-infection treatment. The added product supports a positive read, though the report gives no sales figures.
An Apple expert changed their mind about the stock, listing the top 5 downgrades for Tuesday.
Bad for ZTSZoetis was cut from Buy to Hold, and its target fell from $103 to $83. The new target remains above Monday's $79.59 close, but the rating cut and lower target show a less favorable view than before.
Zoetis Inc. is adding Iris Knobloch to its Board of Directors, making it bigger starting December 1, 2026.
NeutralZoetis appointed Iris Knobloch to its board and added a board seat. The filing describes no business change, so this does not change how we read the company.
Today, big investors are making moves with 10 health care stocks.
NeutralZoetis's call trade was labeled neutral. The report gives no new company result or plan, so it does not change the company's outlook.
Zoetis shares its earnings results for the second quarter of 2026.
Bad for ZTSZoetis reported lower sales and profit for Q2, and its 2026 forecast calls for further declines. Growth in livestock and pet tests does not outweigh those setbacks.
Zoetis Inc. details changes in leadership with the exit and election of directors, along with the appointment of new officers and their compensation arrangements (ZTS).
NeutralZoetis Inc. has filed a Form 8-K detailing the departure and appointment of certain directors and officers, which could lead to changes in leadership dynamics and strategic direction. Investors should monitor how these changes may affect the company's operations and stock performance.
Facing reduced demand in pet healthcare, Zoetis is adjusting its commercial approach to tackle challenges.
NeutralZoetis Inc. reported second-quarter earnings that slightly exceeded expectations, but the company highlighted a decline in demand for companion animal products and increased competition, which raises concerns about future revenue growth. The mixed results and challenges in the market could lead to negative sentiment among investors.